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Malaria infections remain a serious global health problem in the world, particularly
among children and pregnant women in Sub-Saharan Africa. Moreover, malaria control
and elimination is hampered by rapid development of resistance by the parasite
and the vector to commonly used antimalarial drugs and insecticides, respectively.
Therefore, vaccine-based strategies are sorely needed, including those designed to
interrupt disease transmission. However, a prerequisite for such a vaccine strategy
is the understanding of both the human and vector immune responses to parasite
developmental stages involved in parasite transmission in both man and mosquito. Here,
we review the naturally acquired humoral and cellular responses to sexual stages of
the parasite while in the human host and the Anopheles vector. In addition, updates on
current anti-gametocyte, anti-gamete, and anti-mosquito transmission blocking vaccines
are given. We conclude with our views on some important future directions of research
into P. falciparum sexual stage immunity relevant to the search for the most appropriate
transmission-blocking vaccine.
Keywords: Plasmodium falciparum, gametocytes, humoral immunity, cellular immunity, mosquito immunity
INTRODUCTION
Malaria is one of the most important parasitic infections with the highest burden of mortality and Q6
morbidity in sub-Saharan Africa. Despite progress and advances in the strategies to control the Q8
disease, malaria claimed the lives of approximately 445,000 people from among 216 million clinical
cases globally in 2016; mostly in children under 5 years and pregnant women as reported by WHO
(1). The increasing challenges posed by the emergence of resistance to antimalarials by malaria
parasites and to insecticides by mosquitoes (2, 3) suggest the need for additional interventions
aiming at transmission reduction such as vaccines. Moreover, targeting of multiple stages of the
parasites might be the best strategy for any successful malaria vaccine (4), further highlighting the
need for continuous identification and validation of alternative and effective targets.
Transmission blocking interventions either targeting gametocytes while in the human host or
gametes in the mosquito are considered an essential part of malaria control strategies especially
in the quest to eradicate malaria (5, 6). Malaria parasites (sporozoites) are transmitted through
the bite of Anopheline mosquitoes. Once in the human system, the sporozoites migrate to the
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liver where they undergo pre-erythrocytic multiplication
(schizogony) leading to the production of merozoites that
move into the bloodstream (erythrocytic stage; Figure 1). The
pathology results from red blood cell (RBCs) invasion and
further asexual replication of parasites within RBCs (erythrocytic
schizogony) leading to massive RBC lysis, disrupted blood flow
due to cytoadherence of parasite-infected RBCs to endothelial
surfaces, anemia, and inflammation that may be lethal if
untreated. Gametocytes are specialized stages of Plasmodium
parasites that are essential for transmission from humans to
mosquitoes. Initially, a certain proportion of the erythrocytic
stage parasites undergoes a permanent differentiation
also referred to as sexual commitment into both male
(microgametocyte) and female (macrogametocyte) gametocytes
(Figure 1). This process is known as gametocytogenesis (7, 8).
Sexually committed ring stage trophozoites from erythrocytic
stages in peripheral circulation (9, 10) progress into gametocyte
developmental stages 1 to IV while sequestered in bone marrow
compartments (11–14). This constitutes the main reason why
only late gametocyte stages are found in peripheral circulation.
Early gametocytes are thought to sequester in tissues such as
spleen and bone marrow through parasite-host interactions
via parasite molecules less elucidated but probably PfEMP1,
STEVORS, or RIFINS (14–16). The human host endothelial
receptors mediating sequestration of developing gametocytes
in the bone marrow and other organs however remain
unidentified (17). Differentiation of male and female gametocytes
occur during sexual commitment where the asexual precursor,
schizont, give rise to either male or female gametocytes (7, 8).
After about 10–12 days of sequestered development, mature,
male, and female gametocytes emerge and circulate in peripheral
blood for a variable amount of time until taken up by mosquitoes
(18, 19). Gametocytes do not replicate; however, hemoglobin
digestion continues until they reach stage IV (20). In addition,
gametocyte-specific mRNAs are produced and a subset of these,
important for their stage development in the mosquito, are
translationally repressed until gametocytes are taken up by the
vector when they go back to peripheral circulation (21). The
phenomenon governing the return of mature gametocytes in
the peripheral blood is not clearly understood. Once ingested,
gametocytes rapidly transform into male (microgamete) and
female gametes (macrogamete) in response to environmental
cues such as a rise in pH, reduction in temperature and exposure
to xanthurenic acid (22). Exflagellation (male gamete induction)
is followed by the expression of gamete-specific proteins (23).
Fertilization of macrogametocytes by microgametes is preceded
by 3 rounds of DNA replication by male gametocytes giving
rise to 8 motile microgametes resulting in a zygote (Figure 1).
The zygote elongates to form an ookinete which crosses the
midgut wall to develop into an oocyst. Further cell divisions and
development of the oocyst give rise to sporozoites. Following
oocyst capsule rupture, thousands of sporozoites emerge and
invade the mosquito salivary glands which then render the vector
infectious to humans during a bloodmeal, thus completing the
transmission cycle (24–26) (Figure 1).
The infectiousness and transmission potential of gametocytes
is influenced by their prevalence and density (27), degree of
maturity (28), and both mosquito and human immune responses
(29, 30). Furthermore, the efficiency of transmission depends on
the generation of sporozoites and therefore level of infectivity
or sporozoite dose transmitted (31). Moreover, the sporogonic
stages are exposed to the vector’s natural immune responses (32–
34). It should be pointed out that gametocyte infectiousness refers
to the amount of mature gametocytes that can potently infect
the mosquito (demonstrated by their ability to undergo further
development) after ingestion whereas sporozoite infectivity refers
to the dose of potent sporozoites capable of being transmitted to
humans during subsequent blood meals.
Here, we review the available evidence for naturally
acquired human immune responses against the sexual stages
of Plasmodium parasites targeting gametocytes and gametes in
human and mosquito hosts, respectively. The mosquito immune
responses against the development of these sexual stages in
the midgut are also discussed, and propositions are made for
future research directions toward the design of appropriate
transmission blocking vaccines.
NATURALLY ACQUIRED ANTIBODY
RESPONSES TO GAMETOCYTE AND
GAMETE ANTIGENS
For over three decades now there have been some efforts
to illuminate antibody responses to gametocyte and gamete
development in mosquitoes and their potential for transmission
reducing immunity (TRI). TRI is based on observations of
naturally acquired antibodies against gametocytes that are
produced in the human host in response to proteins of
gametocytes that were not taken up by mosquitoes (35). When
these gametocytes die, they release intracellular proteins/antigens
into the host circulation. Among these are proteins produced
in gametocytes which are crucial for the extracellular parasite
development in the mosquito midgut (36, 37). These antigens
are then processed and presented by antigen presenting cells
eventually eliciting humoral immune responses, which can
cause substantial or complete blockade of parasite development
(gametogenesis, fertilization) in the mosquito. This is the essence
of TRI and forms the basis for the development of transmission-
blocking vaccines (TBV). TRI occurs when human antibodies,
taken up by a mosquito in a potentially infectious blood-meal
containing male and female gametocytes, are able to prevent
fertilization and/or development of ookinetes/oocyts/sporozoites
in the mosquito and thus infection of the mosquito (38, 39).
Extensively studied antigens to date include
gametocyte/gamete proteins such as Pfs230 and Pfs45/48
and the zygote/ookinete proteins Pfs25 and Pfs28 (37) also
known as the TBV candidate (30, 37, 40–43). Anti-Pfs230
and Pfs48/45 antibodies target the so-called pre-fertilization
phase while anti-Pfs25 and anti-Pfs28 antibodies represent the
post-fertilization phases marked by the differences in the parasite
stage and target antigens. As such parasite proteins are referred
to as Pre- and post-fertilization antigens, respectively. Binding
of these antibodies to their antigen either blocks their function
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FIGURE 1 | Life cycle of P. falciparum development in the human host and mosquito vector. (1). Mosquito’s bite and release sporozoites into the human host followedQ4
Q5 by migration into the liver. (2). Pre-erythrocytic schizogony: infection of hepatocytes and asexual multiplication of the parasites in the liver. (3). Erythrocytic schizogony:
translocation of parasites from the liver into the bloodstream accompanied by asexual multiplication and release of merozoites upon RBC rupture. (4). Gametocyte
generation: sexual commitment, sequestration of early gametocytes, maturation in tissues and release of mature gametocytes in blood (ready to be picked up by the
vector). (5). Parasite development in the mosquito midgut: exflagellation of male gametocytes prior to fertilization which yields the zygote which undergoes further
development into a motile ookinete. (6). Parasite development in the mosquito salivary gland: oocyst formation, sporozoite development, and release in the mosquito
salivary gland (ready to be transmitted to the human host during subsequent mosquito bites).
essential for parasite development or facilitates complement-
mediated gamete killing as shown for antibodies against Pfs230
(44).
Naturally occurring antibodies targeting Pfs230 and Pfs45/48
have been observed in field studies in The Gambia, Kenya,
and Cameroon and were associated with reduced malaria
transmission (30, 45). However, other studies reported that
transmission reduction correlated with antibody responses to
Pfs230 only (46) or with anti-Pfs48/45 antibodies only (6, 42,
43). These conflicting results may be due to differences in the
history of exposure of study participants or existence of other
co-infections.
A recent study by Stone et al. using field-based mosquito-
feeding assays found mosquito infection rate to be significantly
reduced for people harboring naturally acquired anti-Pfs48/45
and anti-Pfs230 antibodies. In addition, these antibodies
were shown to be host gametocyte density-dependent and
mechanistically associated with transmission reducing activity
(TRA) (47, 48). In the same study, using protein microarray,
43 novel gametocyte proteins whose specific antibodies were
associated with TRA were also identified (48). Among these 43
proteins, 16 predicted to be surface-expressed showed responses
more similar to those of Pfs48/45 and Pfs230 in terms of TRA
and as such warrant further investigations and characterization
as TBV candidates (48, 49). However, the increase of natural
seroprevalence to Pfs48/45 and Pfs230 with age found by
Stone and colleagues did not corroborate a previous study by
Ouedraogo et al. (2011). Q10
It is worth noting that antibodies against the post-fertilization
antigens Pfs25 and Pfs28 have not been observed because these
antigens are not exposed to the human immune system. If
utilized in a vaccine, post-fertilization antibodies would not be
boosted by natural malaria infections in vaccinated individuals.
Nevertheless, antibodies against Pfs28 and Pfs25 have shown
promise in blocking mosquito stage development and therefore
transmission in in vitro experiments and are currently being
evaluated in clinical trials (50).
The development and evaluation of antibody responses to
all gametocyte/gamete-specific antigens and their effect on
sexual stages in the mosquito faces several challenges (50).
First, evaluation of transmission reducing immunity relies
heavily on mosquito feeding experiments, otherwise known as
standard membrane feeding assays, where gametocyte-infected
blood is fed to mosquitoes with or without antibodies to the
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respective antigens. Dissection of mosquitoes 7 days after blood
feeding for oocyt counts is used as an indirect measure of
transmission blocking activity. These assays are time-consuming
and labor-intensive. Second, it is not known what ingested
antibody levels in the mosquito are required that would lead
to a subsequent transmission blockade. The identification and
validation of gametocyte surface antigens as vaccine candidates
with transmission reducing activity (TRA) directly measurable in
the human host will overcome these challenges, complement and
strengthen current transmission blocking vaccine efforts (6, 51).
NATURALLY ACQUIRED ANTIBODY
RESPONSES TO THE SURFACE OF
GAMETOCYTE-INFECTED
ERYTHROCYTES
It has been difficult to elucidate naturally acquired antibody
responses to gametocyte-infected erythrocyte surface antigens
(GSAs), distinct from those recognizing internally expressed
gametocyte and gamete antigens, in natural human infections.
This is largely due to the indirect effect of asexual stage immunity
on the prevalence and density of gametocytes.
Naturally acquired sexual stage antibodies are known
to be produced against P. falciparum gametocyte-infected
erythrocyte surface antigens in human peripheral circulation
(anti-gametocyte immunity) (4, 52). There are very few studies
on human immune responses recognizing gametocyte-infected
erythrocyte surface antigens referred to as anti- gametocyte
immunity. This is in contrast to anti-gamete immunity which is
raised against intracellular proteins of dead gametocytes which
have some function at the gamete stages, or more broadly
immune responses to gamete surface antigens (4, 6, 31, 51–53).
In the first investigation of its kind, plasma antibodies from
gametocytemic Gambian children donated after antimalarial
treatment were used to detect antigens on the surface of
3D7 cultured mature stage V gametocytes. Surprisingly, no
antibody recognition of the surface of erythrocytes infected
with developing gametocytes, stages I-IV, representing the stages
known to be sequestered in deep tissues, were found (44, 53). In
addition, children harboring these anti-GSA antibody responses
were significantly less likely to carry gametocytes after subsequent
infections suggesting an ability to control gametocytemia in these
patients. It was also shown that malaria patient plasma samples
with strong anti-GSA plasma antibody recognition of the mature
gametocyte-infected erythrocyte surface were not more likely
to recognize the surface of erythrocytes infected with asexual
parasites and vice versa (53).
This was a proof of concept for the rationale to develop
an anti-GSA transmission blocking vaccine. It derived its
basis from epidemiological observations of specific immune
suppression of gametocytes in Indonesia (52). P. falciparum
gametocyte rates were reduced among semi-immune native
Papuans, independent of immune control of asexual parasitemia,
when compared to a transmigrant Javanese population with
a history of lower malaria exposure. These findings suggest
specific immune control of gametocytemia as the observations
could not be explained by differences in the frequency or grade
of parasitemia, illness or by known patterns of antimalarial
treatment. Further, immunofluorescence tests with acetone-fixed
whole gametocytes showed a correlation between antibody levels
and reduced gametocytemia among the native Irianese (52).
The important observations by Saeed et al. (53), the ability of
patient plasma to recognize GSA and the significant association
with reduced gametocyte carriage, required further investigation.
In order to rule out the fact that patient plasma antibody
recognition of GSA on mature stage V gametocytes was not a
deficiency or artifact of the 3D7 clone, we carried out recognition
studies in plasma antibody samples from Ghanaian school
children from a high endemicity region, against both a recent
isolate and 3D7. In this study, plasma from asymptomatic school
children collected over 5 sampling times at weekly intervals were
tested against the surface of 3D7 mature gametocyte-infected
erythrocytes as well as mature gametocytes derived from a 2012
clinical isolate of Kenyan origin, HL1204. Interestingly, we found
plasma antibodies from all children bind to GSA of gametocytes
derived from both clones to at least some extent. It was
striking to note that plasma from Ghanaian children recognized
the GSA on mature gametocytes of Kenyan origin, suggesting
that perhaps the antigens detected might be conserved across
geographical locations. Immature gametocytes from the clinical
isolate were also tested against a selected number of plasma
samples from Ghanaian children with strong anti-GSA antibody
responses. Similar to the observations of Saeed et al. (53),
no detectable recognition of GSA to asynchronous immature
gametocytes was observed. These findings were corroborated
by some gametocyte adhesion studies (15, 54), which posit
that maturing gametocytes do not, as previously thought,
sequester from peripheral circulation through adhesion to
human bone marrow-derived endothelial surfaces and receptors
(55–57). Nevertheless, further studies with tightly synchronized
immature gametocyte preparations are required before we can
rule out the possibility that developing gametocytes express
adhesins involved in parasite ligand-host receptor interactions
which mediates sequestration and elicit gametocyte-specific
immunity (4).
To further test the prevalence of anti-GSA antibodies in the
general endemic population, plasma donated bymicroscopically-
confirmed parasite negative individuals were tested for antibody
recognition to GSA. Forty-eight percent (24/50) of parasite-
negative children and adults recognized the surface of mature
gametocyte-infected erythrocytes (4, 58). Since submicroscopic
gametocytemia could not be excluded, anti-GSA antibody
carriage in cohort studies utilizing sensitive gametocyte detection
methods such as RT-qPCR or QT-NASBA are needed to fully
illuminate this relationship. Moreover, testing plasma donated
from both gametocyte positive and negative children showed
that our findings could possibly represent the general malaria-
infected population. In addition, evidence was found that
children who harbored anti-GSA antibodies were significantly
but weakly associated with lower risk of gametocyte carriage
(4). In addition, preliminary indirect evidence suggest that anti-
GSA antibodies may be maintained over a period of time
(4, 58).
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CELLULAR IMMUNE RESPONSES TO
GAMETOCYTES WHILE IN THE HUMAN
HOST
Studies aiming at evaluating the cellular immune responses to the
sexual stages compared to asexual ones of Plasmodium species
are limited. However, there is evidence that such immunity
exists. The transfer of T-cells from gamete-immunized mice
was shown in the 1980s to markedly reduce gametocytemia in
the recipient mice using the rodent species P. yoelii nigeriensis
(59). Recipient mice also failed to effectively infect the mosquito
vector A. stephensi as demonstrated by direct blood feeding (up
to 95% transmission reduction) suggesting the direct impact of
T-cells on transmission. However, the T-cell transfer had no
effects on asexual stages (59). Good et al. (60) further showed
that peripheral blood from non-exposed individuals contains T
cells (clone) which proliferate and up-regulate interferon-gamma
production upon stimulation with mature gametocyte-infected
RBCs lysate. Similar results were also obtained in a hyper-
endemic region in The Gambia by stimulation of peripheral
blood mononuclear cells (PBMCs) of volunteers by gametocyte
lysate (61). The detection of gametocyte-specific antibodies in
the study participants by ELISA implied previous exposure to
sexual stage parasites. Findings from this study suggest a T cell-
dependent suppression of gametocytes or T cells helping B cells to
fight against the malaria infection. Both asexual and sexual stage-
specific antigens have equally been shown to elicit polyclonal T-
cell responses in malaria non-exposed individuals (62). However,
the reaction is not peculiar to gametocytes since it has been
demonstrated that CD4T Cells from non-exposed individuals
react with PfEMP-1 via a Major Histocompatibility Complex
(MHC) Class II-T cell receptor-independent Pathway (63). This
could be associated to cross-reactivity from other infections.
Whether this phenomenon is protective in children is not known.
In other studies, an increase in cytokine production such as
TNF-α and IFN-γ was demonstrated in monkeys and humans
infected with P. cynomolgi and P. vivax, respectively (64, 65).
The increase in cytokine secretion correlated with the decrease
in parasitemia and the inability of gametocytes to infect the
mosquito vector and as such, cytokines and other PMBC-derived
components (nitric oxide, antibodies) were believed to play a role
in the loss of infectivity (65, 66). In their study in 1993, Naotunne
et al. showed that the effect of PBMC-derived components on
gametocyte infectivity was closely linked to the presence of
white blood cells as no effect was seen in their absence (66).
This negative effect on the infectivity of gametocytes appeared
to be reversed in the presence of high concentration of an L-
arginine analog (NGL-monomethyl arginine acetate) (67). This
suggests that gametocyte inactivation in the presence of WBCs is
achieved through an L-arginine-associated pathway mechanism.
In the same line, an in vitro study conducted by Smith et al.
(68) revealed that P. falciparum stage I and IIA gametocytes
are to a large extent eliminated from the circulation by non-
opsonic phagocytosis mediated by monocytes and macrophages.
They showed through antibody inhibition assays and enzyme
treatment that the interaction of PfEMP-1 and CD36 plays a
major role in this innate defense against early gametocytes stages.
This is in line with a previous study reporting the interaction of P.
falciparum early gametocytes with CD36 receptor (69). A recent
study conducted in India demonstrated a significant negative
association between gametocytemia and IFN-γ in children (70).
Gametocyte-specific exoantigens (from gametocyte culture
supernatants) have been shown to be able to stimulate the
proliferation and activation of lymphocytes from P. falciparum
exposed individual (71). In this study, T cell receptors
gamma/delta (TCR γδ+), and CD3+ CD8+ and CD3+ CD4−
CD8− T cells were found to be up-regulated upon sensitization
with these exoantigens. Particularly, the expression of the
activation marker CD25+ increased on stimulated CD3+ and γδ
T cells. The frequency of γδ T cells had previously been found to
increase in the course of acutemalaria (72). However, it is difficult
to ascertain the specificity of the exoantigens because they could
as well be coming from ruptured or dead asexual parasite iRBCs.
As already indicated, there is a paucity of information on cellular
immunity to gametocytes. Therefore, further investigations into
the role of cellular immune responses to gametocytes andmalaria
transmission; and the identification/validation of the antigens
involved, in a bid to contribute toward the development of an
effective transmission blocking vaccine are required.
CELLULAR IMMUNITY TO SEXUAL
STAGES WHILE IN THE MOSQUITO
VECTOR
In the mosquito vector, killing of malaria parasites is not
only mediated by vertebrate host-derived molecules but also
by mosquito components as has previously been demonstrated
(32–34). Studies have shown that only a small proportion of
gametocytes ingested in the blood meal by the mosquito vector
is transformed into oocysts and sporozoites; and only about 38%
of mosquitoes that take gametocyte-containing blood become
infected (32, 33, 73). This is largely due to the peritrophic
membrane or matrix (PM) which constitutes a physical barrier
to Plasmodium species and other pathogens (33, 74, 75). This
membrane is formed after the ingestion of a potentially infectious
blood meal by the mosquito and surrounds the ingested blood.
It prevents direct contact between the pathogens in the blood
and the midgut epithelium and by so doing interferes with
midgut invasion (33, 75). However, ookinetes secrete the enzyme
chitinase which destroys the chitineous PM and allows it to
invade the midgut (33, 76). The midgut epithelial cells are also
thought to secrete high amounts of nitric oxide synthase and
peroxidases, which in turn leads to nitration of the gut epithelium
with subsequent tagging of ookinetes for destruction by the
complement system (33, 77, 78).
The innate immune response in the malaria mosquito vector
is mediated mainly by hemocytes which eliminate pathogens
such as bacteria, fungi, and protozoa by phagocytosis (79–
81). The Anopheles species and other insects are known to
have a complement C3-like protein called thioester-containing
proteins (TEP) (79). TEP of A. gambiae (AgTEP1) has been
shown to be valuable for the initiation of immune defense
against P. berghei. TEP1 plays the role of opsonins and facilitates
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the interaction between the parasite and the hemocytes with
subsequent encapsulation, and killing of the parasite (79).
Double knock-out of the TEP1 gene renders genetically selected
refractory Anopheles strain susceptible to infection and increases
the infectivity rates in susceptible A. gambiae (79). This vector
defense mechanism has been shown recently to be by-passed by
P. falciparum through its 6-cysteine protein P47-like (82). This
protein is invaluable for P. berghei female gamete fertility (83)
but in P. falciparum, it promotes the gametocyte-to-ookinete
development and protects the ookinete from complement-
dependent lysis (82).
In addition, infection of A. gambiae mosquito by ookinetes
of P. berghei has been demonstrated to modulate the mosquito’s
immune system by up-regulating the expression of the
antibacterial peptide defensin and a putative gram-negative
bacteria-binding protein (84), and a TNF-α factor-like
transcription factor (LL3) (85). Silencing of the LL3 gene
was found to be associated with an increase in parasite survival,
confirming its role in conferring mosquito resistance to the
Plasmodium parasite. LL3 also affects the expression of another
protein, a serine protease inhibitor (SRPN6), which equally
confers resistance to invasion by Plasmodium (85).
Genomic and transcriptomic analyses of bacterial
lipopolysaccharide-stimulated A. gambiae mosquitos revealed
23 immune-regulated genes which include putative protease
inhibitors, serine proteases, and regulatory molecules (86).
Interestingly, the protease inhibitor α-2-macroglobulin was
found to be more specific in response to malaria parasite
than bacterial infection as observed with mosquitoes fed on
a P. berghei-infected hamster. This suggests that the immune
response mounted by the mosquito vector may be pathogen
specific, and other authors have reported similar findings (87).
RNA gene interference (RNAi) experiments on P. falciparum-
and P. berghei-infected An. gambiae revealed some common
genes that confer resistance to both parasite species. However,
other genes were found to exhibit species-specificity, conferring
resistance only to one parasite species, namely a pattern
recognition receptor (MD2-like receptor, AgMDL1) and an
immunolectin, FBN39 for P. falciparum and the antimicrobial
peptide gambicin and a novel putative short secreted peptide,
IRSP5 for P. berghei (87). Together, these findings show that
mosquitoes express molecules with anti-plasmodial properties
which act as self-defense mechanism in the vector.
ANTI-GAMETOCYTE AND ANTI-GAMETE
TRANSMISSION BLOCKING VACCINES
Up to date, it has been a difficult task developing an effective
vaccine against malaria. This is due both to the complexity of
the Plasmodium parasite life cycle and the polymorphic nature
of its antigens (88, 89). However, the hope that an effective
malaria vaccine is feasible is based on the observation that in
endemic regions, clinically immune adults are protected from
severe malaria and death compared to children (88). This could
be attributed to the fact that natural immunity in adults is
probably complex and dependent on immune responses to many
stages. Interestingly, sera from immune individuals have been
shown to inhibit gamete fertilization and development in the
mosquito vector thereby interfering with disease transmission
(90–92). This constitutes the basis of the development of malaria
transmission blocking vaccines (TBVs). An emerging concept
is to develop vaccines against antigens expressed solely in
the mosquito’s midgut to which the host immune system is
not naturally exposed. Antibodies against those antigens from
vaccinated individuals and animals have been shown to interfere
with parasite viability and development in the mosquito midgut
interaction (93–95).
As a limitation, TBVs are different from the other vaccine
types (liver and blood stage vaccines) in the sense that they do not
protect against disease in the vaccines. However, they reduce the
risk of transmission to other people by the mosquito vector and
by so doing favor herd immunity; as such they have sometimes
been referred to as altruistic vaccines (94). Two groups of target
antigens (gene superfamilies) exist, namely pre-fertilization
and post-fertilization antigens (Table 1 and Figure 2) (48, 96,
106–110, 120). The list (Table 1) is not exhaustive both for
pre- and post-fertilization antigens as some proteins remain
unidentified to date. Some of these target antigens were
characterized back in 1983 by Kaushal et al. (97), among
them, Pfs48/45, Pfs47, Pfs230, and Pfs25 are immunogenic and
less polymorphic, making them good vaccine candidates (121).
Their use in combination with strong adjuvants or carrier
proteins has been shown to boost their immunogenicity. Some
of the adjuvants/carrier proteins used included Maltose Binding
Protein (MBP)—Exoprotein A (EPA) from P. aeruginosa—Outer
Membrane Protein Complex (OMPC)—modified Lickenase
carrier (LiKM)—Virus-like particle (VLP)—Alhydrogel. Only
two of these vaccine candidates, namely Pfs 230 and Pfs25,
have entered clinical trial stage (122) and are reviewed in this
paper. The potential of the other antigens (e.g., Pfs48/45) as
TBV candidates has been recently reviewed by Chaturvedi et al.
(121). Although Pfs 45/48 has not yet attained the clinical trial
phase, previous studies demonstrated that antibodies against
this antigen elicit up to 99% inhibition of oocyst intensity and
85% inhibition of oocyst prevalence (98). Hence the necessity
to pursue studies with the Pfs 48/45 TBV candidate. Moreover,
recent studies have identified new sexual stage antigens that
require more attention (48, 120)
Pfs230 is a 363 kDa protein and a potent antigen of malaria
TBV. It is a main component in the fertilization process as male
gametes with impaired Pfs230 gene are incapable of interacting
with red blood cells (RBCs) and forming exflagellation centers
(99). This results in marked reduction in oocyst production
and mosquito infectivity. Similar observations were made with
genetically modified P. falciparum with a truncated chitinase 1
(PfCHT1) gene which could be due to the inability of affected
ookinetes to invade the mosquito midgut (105). Administration
of recombinant Pfs230 + Alhydrogel induced high titers of
antibodies in rabbits which were found to have significant
transmission reducing activity (100). It should be pointed out
that only certain fragments of the recombinant Pfs230 antigen
induce responses that lead to TRA (98). Significant associations
between suppression of mosquito infectivity and anti-Pfs230
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TABLE 1 | Sexual stage antigens in the human host and mosquito vector with transmission reducing activity/potentials.Q5
Q14
Type Antigen name Function/role References
Parasite pre-fertilization antigens Pfs48/45 Male gamete attachment to female gamete (6, 30, 42, 43, 96, 97)
Pfs47 Fertilization process (96, 97)
Pfs230 Main component in the male fertilization process (30, 41, 97–100)
STEVORS Sequestration of early gametocytes and
deformability of mature gametocytes
(14–16)
Plasmodium falciparum surface related antigen
(PfSRA)
Erythrocyte invasion, unknown role in gametocytes (101)
Plasmodium falciparum LCCL
domain-containing protein (CCP)
Parasite development in the mosquito (102)
Plasmodium falciparum CX3CL1-binding
protein 2
Cytoadherence to host cells (103)
Plasmodium falciparum Gametocyte EXported
Protein-5 (PfGEXP5)
Gametocyte switching (104)
Parasite post-fertilization antigens Pf25 Parasite survival and interactions with mosquito
midgut
(37, 50, 97)
Pfs28 Parasite survival and interactions with mosquito
midgut
(37, 50, 97)
Chitinase 1 Parasite invasion of the midgut (33, 76, 105)
Von Willebrand factor-A domain-related protein
(WARP)
Ookinete attachment to the mosquito midgut,
differentiation of ookinete to oocyst
(106)
Circumsporozoite and thrombospondin-related
anonymous protein (CTRP)
Transition from ookinetes into oocysts in the vector (107)
Membrane-attack ookinete protein (MAOP) Ookinete midgut invasion in vector (108)
Secreted ookinete adhesive protein (SOAP) Ookinete midgut invasion and oocyst development (109)
Cell-traversal protein for ookinetes and
sporozoites (CelTOS)
Establishment of malaria infections in both vector
and vertebrate hosts
(110)
Vector antigens Midgut-specific alanyl aminopeptidase
(AnAPN1)
Ookinete midgut invasion in vector (74, 111–114)
Carboxypeptidase B1 Parasite development in the vector (115, 116)
Serine protease inhibitors (serpins) Regulation of the vector innate immune responses (117)
Saglin proteins Vector salivary gland invasion (118, 119)
antibody levels were also found using membrane feeding assays
with sera collected from African populations (43, 45, 46, 123)
and in mice (98). This vaccine candidate (124) has entered a
phase 1 clinical trial in which the Safety and Immunogenicity
of Pfs230D1M-EPA/Alhydrogel is being evaluated in adults in
the US and Mali (data unpublished, https://clinicaltrials.gov/ct2/
show/NCT02334462).
Pf25 is relevant for parasite survival and interactions
with mosquito midgut molecules prior to invasion. Anti-Pf25
antibodies have been shown to halt parasite growth within the
mosquito in membrane feeding assays as reviewed by Chaturvedi
et al. (121). This vaccine candidate has undergone clinical trial
phase 1 in combination with different carriers and adjuvants.
Administration of Pf25-Viral-like-particles plus Alhydrogel R© to
mice resulted in high antibody titers with 100% transmission
reducing activity (TRA) throughout the study (125). A clinical
trial phase 1a with this combination was recently carried
out in the United States (https://clinicaltrials.gov/ct2/show/
NCT02013687). It appeared that the combination is safe with
no serious adverse reactions observed in healthy volunteers even
when higher doses are administered. However, the antibodies
generated showed low TRA hence the necessity to prioritize
vaccine adjuvant formulations for further investigations (126).
Another combination of Pfs25 and EPA (Pseudomonas
aeruginosa ExoProtein A) plus Alhydrogel R© was also
demonstrated to be well tolerated by naïve individuals after
several doses in a phase 1a dose-response clinical trial in the
US which correlated with antibody titers (127). A Phase 1b
trial of Pfs25-EPA/Alhydrogel R© is currently ongoing in Malian
adults (121). New promising multimeric Pf25-based Vaccine
Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
have recently been developed with promising results (128) and
are now undergoing clinical trial phase 1a in the UK. These
vaccine candidates consist of attenuated viruses (ChAd63-
chimpanzee adenovirus 63 and MVA- modified vaccinia Ankara)
encoding the parasite protein Pf25, which are fused to a carrier
protein (IMX313-multimerization technology) as adjuvant
(NCT02532049). In mouse models, Chad63Pfs25-IMX313 was
safe and significantly more immunogenic with higher TRA than
monomeric Pfs25 (129). Similar results were obtained with the
P. vivax antigen (Pvs25H/Alhydrogel), and the P. falciparum
ortholog Pfs25 in a mouse model. Anti-Pvs25H antibody
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FIGURE 2 | Potential approaches for new vaccine candidate identification and vaccine development. This figure describes in a nutshell the life cycle of the
Plasmodium species providing different stage-specific antigens and the strategies that could be used to develop more efficacious vaccine by combining potential
vaccine candidates from various stages (host’s and vector’s). Uncharacterized and unknown antigens refer to proteins of unknown functions or proteins that have only
been partially characterized such as the multigene families (var, rif, and stevor). The function of the proteins encoded by these multigene families have been
tremendously studied in the asexual stages of Plasmodium but poorly exploited in their sexual counterparts. We propose that more attention should be paid to the
sexual stages in terms of vaccine candidate identification and characterization. Nowadays, this could easily be done with the advent of Omics technologies. PfEMP-1,
Plasmodium falciparum erythrocyte membrane protein-1; RIFINs, repetitive interspersed families of polypeptides; STEVORs, Subtelomeric variable open reading frame
polypeptides; MSPs, Merozoite surface proteins; VAR2CSA, A variant of PfEMP-1 with high affinity to placental tissues; PfRHs, Plasmodium falciparum reticulocyte
binding protein homologs; EBAs, Erythrocyte binding antigens; AMAs, Apical membrane antigens; CSP, Circumsporozoite protein; LSA-1, Liver-Stage Antigen;
mTRAP, Merozoite thrombospondin-related anonymous protein; Pfs (230, 48/45, 25,28), Plasmodium falciparum gamete surface proteins (molecular weight in dalton);
WARP, von Willebrand factor-A domain-related protein; CTRP, Circumsporozoite and TRAP-related protein; MAOP, Membrane-attack ookinete protein; SOAP,
Secreted ookinete adhesive protein; CelTos, Cell-traversal protein for ookinetes and sporozoites; AnAPN1, An. Gambiae alanyl aminopeptidase; serpins, Serine
protease inhibitors; saglin proteins.
levels peaked after the third vaccination and vaccine-induced
antibodies were functional, giving significant TRA (95). This
combination has proven to be safe in humans in a clinical trial
phase 1 with similar immunogenicity and TRA as previously
shown in mice (130).
The main limitations of these sexual stage vaccine candidates
have been the systemic reactogenicity observed in some clinical
trials, short-lasting antibody responses owing to the fact that
the host has no or limited exposure to the antigens requiring
multiple boosting doses and strong adjuvants. In addition the
recombinant antigens are difficult to express in their native
form (121). To circumvent the issue of limited exposure of
pre-fertilization and post-fertilization antigens to the human
immune system, it might be good to develop DNA or viral
vector-based vaccines containing different antigens (131, 132).
This ensures continuous production of the antigens of interest
in the host hence permanent stimulation of the immune system,
thus bypassing the necessity for multiple immunizations (131,
132). However, the main problem is that the attenuated virus
used can revert and cause infections, it can also get integrated
in the vaccinee’s genome and lead to unforeseen consequences
with the associated ethical issues. It would be valuable to make
use of high class adjuvants such as the Polymeric nanoparticle-
and microparticle-based adjuvant systems that ensure long term
delivery of the antigen to the host system when administered
(133). It would be good also to include some blood and liver stage
antigens to such combinations so that the vaccinee benefits from
the process (Figure 2).
ANTI-MOSQUITO TRANSMISSION
BLOCKING VACCINES
Some mosquito components are invaluable for the sporogonic
development of malaria parasites as they are involved in parasite
invasion through interaction with parasite receptors. Antibodies
raised against these components could be very useful in blocking
parasite development in the mosquito vector (94). Thus, these
components constitute another class of TBV candidates as their
inhibition would likely minimize the risk of new infection in the
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community (134). An alternative transmission blocking vaccine
strategy could be to interfere with the interactions between
the parasite and the midgut molecules of the mosquito vector
which will lead to the inhibition of ookinete invasion and the
development of mosquito stages. Many of such molecules have
been identified and characterized (Table 1 and Figure 2). These
molecules have been shown to be more conserved than the
parasite antigens and are immunogenic in non-human primates
(74, 111–114).
Midgut-specific alanyl aminopeptidase (AnAPN1) is a
Glycosylphosphatidyl inositol (GPI)-anchored antigen which
plays a valuable role in ookinete invasion in A. gambiae as
previously shown by Dinglasan et al. (112). Administration of
a recombinant fragment of rAnAPN160–195 with Alhydrogel
has been demonstrated to stimulate a sustained production of
antibodies with transmission blocking activities as revealed by
membrane feeding assays (111). The TRA was dose dependent
with higher antibody levels attaining 100% efficacy, and
functional in both the chromosomal M and S forms of A.
gambiae vectors. Moreover, the P. falciparum-infected blood
samples used for membrane feeding assays were collected
directly from gametocyte positive individuals and the results
obtained exceeded those that had been reported previously with
laboratory strains (112). More importantly, anti rAnAPN160–
195 antibodies had effects on both P. falciparum and P. vivax and
based on that evidence the AnAPN1TBVhas been recommended
for phase I clinical trials (111). This antigen is immunogenic in
mice and rabbits even in the absence of adjuvants (112, 114).
However, it is worth mentioning that another study by Kapulu
et al. failed to replicate the finding reported here. In their
study, anti-AgAPN1 IgG had no significant impact on oocyst
prevalence (98). Antibodies to another GPI-anchored vector
midgut protein, α-AgSGU, were also confirmed to have an effect
on P. falciparum and P. vivax development in An. gambiae and
An. Dirus (113). However, high doses of α-AgSGU antibodies
were required to achieve 80% TRA rendering α-AgSGU less
promising as a TBV target.
The same line, the midgut carboxypeptidase gene of A.
gambiae (cpbAg) has been shown to be up-regulated following
P. falciparum gametocyte ingestion by the vector (115). In
addition, anti-CPBAG antibodies were shown to inhibit the
development of both P. falciparum and P. berghei in the
vector’s midgut. Antibodies directed against CPBA have also
been demonstrated to be vector-unspecific in the sense that they
also inhibit the development of the P. falciparum gametocytes
in A. stephensi mosquitoes, which is the main malaria vector
in Iran and neighboring countries (116). This confirmed the
conserved nature ofmolecules across different vector as predicted
using genomic and proteomic approaches (116) and implies
that a vaccine designed with CPBA could provide cross-species
protection. Thus, CPBA constitutes another promising TBV
candidate.
The interaction between the Plasmodium sporozoite
Thrombospondin Related Anonymous Protein (TRAP) and the
mosquito Saglin proteins is a prerequisite for vector salivary
gland invasion (118). This has been confirmed by in vivo
down regulation experiments of saglin gene expression which
revealed a negative association with salivary gland invasion
(118). Moreover, in silico analysis of saglin revealed the presence
of a signal peptide suggesting that it may be a secreted protein.
If verified in vitro and in vivo, Saglin proteins could constitute
a new promising candidate for TBV design (119). Similarly,
RNA interference silencing and knock-down experiments have
demonstrated the essentiality of the serine protease inhibitors
(serpins) in the survival of An. gambiae and An. stephensi as
well as in the development of parasites (P. berghei) within
these vectors (135, 136). Serpins are regulators of the vector
innate immune responses and they are involved in the clearance
of protozoan parasites (136). Antibodies raised against the
An. gambiae serpin-2 (AgSRPN2) have been shown to be P.
berghei-specific in An. gambiae and An. stephensi as they failed to
interfere with P. falciparum oocyst formation (117). This study
demonstrated that mosquito innate immune response-related
molecules could be used as targets for TBV design; however,
further investigations are needed to identify and/or validate the
right antigens. A limitation here will be that all of these proteins
are likely to suffer from the same problems as gamete/ookinete
antigens in the sense that several booster doses are required and
antibodies may be short-lived.
FUTURE DIRECTIONS IN SEXUAL STAGE
IMMUNITY AND VACCINE DEVELOPMENT
Apart from studies reported in these reviews (59–61, 68, 71, 72),
studies on host cellular and humoral immunity to gametocytes
are scarce if not inexistent. Given promising results in clinical
trials of TBV experimental vaccines for malaria eradication, the
antigens involved should be characterized further to explore
their suitability as vaccine candidates. The generation of long-
lived antibodies depends on the generation of long-lived plasma
cells and memory B cells (MBCs) within germinal centers
(GCs) of secondary lymphoid organs (137). The prerequisite
for plasma cells and MBCs is the interaction between follicular
T helper cells and B cells. Further investigations of these
cell types vis-à-vis the identified antigens in the context of
malaria infections are needed. Similarly, further studies aiming at
identifying new antigens (mainly vector-, gametocyte-, ookinete-
, and/or oocyste-related) using genomics, transcriptomics and
proteomics approaches, the Sanger center parasite gene knock-
out library and other bioinformatics strategies are warranted
(138–140) (Figure 2). These approaches take advantage of next
generation sequencing (NGS) and the availability of growing
numbers of P. falciparum whole genome sequences to identify
new antigens (141). These methods are relatively fast and
high throughput, leading to the identification of a plethora
of essential genes or antigens through comparative analyses
(138, 140–142). The implications of omics in the fight against
infectious disease was recently reviewed by Bah et al. (143).
But this would be strengthened by the concomitant ability to
cultivate the sequenced lines and generate sexual stages from
them for phenotypic studies. Bioinformatic strategies can also
overcome some of the difficulties in studying parasites such
as Plasmodium spp. or Trypanosoma spp. which are genetically
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diverse (139, 144–146). In addition, computer-based algorithms
have been developed to delineate T-cell epitopes on essential
parasite proteins directly from genome sequence data (147–
149). Vaccine developers should consider designing multi-unit
or multi-stage TBVs with components from both the parasite
(precisely gametocyte antigens) and the vector as this will
broaden their spectrum of action.
As far as the search for a vaccine is concerned, much has been
done to understand the multigene family PfEMP-1. However, the
other multigene family proteins such as RIFIN and STEVOR also
constitute an important class of parasite molecules that deserve
attention. These form part of the uncharacterized or partially
characterized parasite antigen repertoire with respect to the
sexual stages (Figure 2). The stevor multicopy family is made up
of a set of 39 genes with 2–3 copies expressed at a time (150) while
about 150–200 genes code for RIFINswithmany copies expressed
at a time as well (151). STEVOR andRIFIN proteins were recently
shown to be implicated in rosetting which is a phenomenon
associated with sequestration and clinical complications of the
malaria (152–156). STEVORs are suspected to be implicated
in the sequestration of early gametocytes in tissues such as
the bone marrow and spleen as well as the deformability of
the mature gametocytes (14–16). There is also evidence that
STEVORs alter RBC membrane rigidity since RBC deformability
has been shown to be linked to STEVOR dissociation from the
mature gametocyte-infected RBC membrane (15). This implies
that inhibiting the functions of STEVORS might negatively affect
the development of gametocytes and by so-doing will also reduce
disease transmission due to a reduced number of sexual stages
being ingested by the mosquito vector during its blood meal.
Despite their variable nature, the putative role of STEVORs
in gametocyte development and sequestration certainly make
this family a possible new class of TBV vaccine targets.
Humoral responses to these antigens have been demonstrated
(157). We therefore recommend further characterization (both
humoral and cellular) of anti-STEVOR immune response, in
the hope of finding additional clues in the search for efficient
TBVs. However, the most pressing task is to develop further
STEVOR-specific reagents demonstrating their relevance in
anti-gametocyte immune responses and therefore transmission
reducing immunity/activities.
In addition to STEVORS, many other Plasmodium antigens
such as LCCL domain-containing protein family (102),
Plasmodium falciparum Surface Related Antigen (PfSRA)
(101), CX3CL1-binding protein 2 (103), Gametocyte EXported
Protein-5 (PfGEXP5) (104) have been described as potential
TBV candidates and as such deserve further characterizations.
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